⌘K
Loading ticker…
As of 2026-08-24, Relay Therapeutics, Inc. Common Stock (RLAY) has a 3-month relative strength percentile of 93 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 93. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 5.1%, relative volume 1.20×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
RLAY is in a stage 2 uptrend, week 11. Currently in a 32-day base; basing ADR 5.3% (broad 7.0%). VCP detected: inconclusive. RS line below base-start high. Distance from 50d / 200d: 4.8% / 59.5%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
RLAY is held by 27 ETFs as of May 2026. Top owner: VTWO at 0.06% weight, $11M notional. Top 3 carry $27M.
Held by 60 ETFs · $242M across latest filings · largest weight 1.60% (SBIO).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTWO | 0.06% | $11M | +0.01 pp |
| SCHASchwab U.S. Small-Cap ETF | 0.05% | $10M | +0.01 pp |
| AVSC | 0.20% | $5M | +0.04 pp |
| VHTVanguard Health Care ETF | 0.03% | $5M | +0.01 pp |
| VFMO | 0.18% | $3M | +0.05 pp |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 1.60% |
| $3M |
| +0.45 pp |
| CANC | 1.28% | $2M | +0.37 pp |
| DWAS | 0.49% | $2M | +0.04 pp |
| VTWV | 0.13% | $2M | +0.03 pp |
| MSSM | 0.19% | $1M | +0.18 pp |
Showing 10 of 27 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RLAY Jan avg: 6.67% median: -0.48% win: 50% σ: 26.73% n: 4 2022-04-12 → 2026-07-31 | RLAY Feb avg: -1.55% median: -7.70% win: 50% σ: 28.20% n: 4 2022-04-12 → 2026-07-31 | RLAY Mar avg: -10.34% median: -10.09% win: 25% σ: 11.78% n: 4 2022-04-12 → 2026-07-31 | RLAY Apr avg: -3.88% median: -21.45% win: 40% σ: 29.94% n: 5 2022-04-12 → 2026-07-31 | RLAY May avg: -7.38% median: -2.02% win: 20% σ: 15.06% n: 5 2022-04-12 → 2026-07-31 | RLAY Jun avg: 13.17% median: 12.75% win: 100% σ: 12.67% n: 5 2022-04-12 → 2026-07-31 | RLAY Jul avg: 8.46% median: 1.73% win: 100% σ: 11.28% n: 5 2022-04-12 → 2026-07-31 | RLAY Aug avg: -3.38% median: -7.70% win: 50% σ: 18.70% n: 4 2022-04-12 → 2026-07-31 (current) | RLAY Sep avg: 7.34% median: 0.83% win: 50% σ: 26.99% n: 4 2022-04-12 → 2026-07-31 | RLAY Oct avg: -1.46% median: -10.54% win: 25% σ: 27.23% n: 4 2022-04-12 → 2026-07-31 | RLAY Nov avg: -0.55% median: -2.73% win: 50% σ: 18.76% n: 4 2022-04-12 → 2026-07-31 | RLAY Dec avg: 3.52% median: -2.76% win: 50% σ: 26.26% n: 4 2022-04-12 → 2026-07-31 |